Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.

(2017) D. H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study.

(2017) J. Blay et al.   JOURNAL OF CLINICAL ONCOLOGY

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

(2011) Paul J. Kostenuik et al.   BONE

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Signal peptide mutations in RANK prevent downstream activation of NF-κB

(2011) Julie C Crockett et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk

(2011) S. Boonen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling

(2011) Wei Tan et al.   NATURE

Matrix-embedded cells control osteoclast formation

(2011) Jinhu Xiong et al.   NATURE MEDICINE

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

(2011) Tomoki Nakashima et al.   NATURE MEDICINE

Receptor activator of NF- B (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit

(2011) V. Duheron et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis

(2010) Jude Canon et al.   BONE

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

(2010) Pamela M. Holland et al.   CANCER BIOLOGY & THERAPY

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Structural and Functional Insights of RANKL-RANK Interaction and Signaling

(2010) C. Liu et al.   JOURNAL OF IMMUNOLOGY

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

(2010) David Thomas et al.   LANCET ONCOLOGY

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

(2010) Eva Gonzalez-Suarez et al.   NATURE

Control of mammary stem cell function by steroid hormone signalling

(2010) Marie-Liesse Asselin-Labat et al.   NATURE

Progesterone induces adult mammary stem cell expansion

(2010) Purna A. Joshi et al.   NATURE

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

(2010) Daniel Schramek et al.   NATURE

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

(2010) S. Ferrari-Lacraz et al.   OSTEOPOROSIS INTERNATIONAL

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland

(2010) M. Beleut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice

(2009) Susann Helas et al.   AMERICAN JOURNAL OF PATHOLOGY

RANK/RANKL: Regulators of Immune Responses and Bone Physiology

(2009) Andreas Leibbrandt et al.   Annals of the New York Academy of Sciences

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin

(2009) Xiaodong Li et al.   BONE

Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats

(2009) Verena Proell et al.   BONE

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium

(2009) K. A. Knoop et al.   JOURNAL OF IMMUNOLOGY

Central control of fever and female body temperature by RANKL/RANK

(2009) Reiko Hanada et al.   NATURE

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

(2008) Vincent Launay-Vacher et al.   BREAST CANCER RESEARCH AND TREATMENT

Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice

(2008) Sean Morony et al.   CIRCULATION

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

(2008) Ann E. Kearns et al.   ENDOCRINE REVIEWS

The Cytokine RANKL Produced by Positively Selected Thymocytes Fosters Medullary Thymic Epithelial Cells that Express Autoimmune Regulator

(2008) Yu Hikosaka et al.   IMMUNITY

The Tumor Necrosis Factor Family Receptors RANK and CD40 Cooperatively Establish the Thymic Medullary Microenvironment and Self-Tolerance

(2008) Taishin Akiyama et al.   IMMUNITY

RANKL Inhibition with Osteoprotegerin Increases Bone Strength by Improving Cortical and Trabecular bone Architecture in Ovariectomized Rats

(2008) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

(2008) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis

(2008) R. E. Miller et al.   MOLECULAR CANCER THERAPEUTICS

Vertebral fracture assessment using standard bone densitometry equipment predicts incident fractures in women

(2008) Mary L Bouxsein et al.   Nature clinical practice. Endocrinology & metabolism